Abstract
See doi:10.1016/S1095-668X(02)00202-6for the article to which this editorial refers. As noted repeatedly, the treatment of in-stent restenosis remains one of the most vexing shortcomings in interventional cardiology. Coronaryrestenosis is often manifested by symptom recurrence, which is translated into an increased rate of repeat revascularization. In this issue, Radke and colleagues1 report the results of a well-conducted meta-analysis with data gathered from published reports of 28 different studies. These studies included a total of 3012 patients with in-stent restenosis treated with six different modalities (stent-in-stent, rotational atherectomy, balloon angioplasty, laser angioplasty, directional atherectomy and vascular brachytherapy) and their clinical outcome at a follow-up of 9±64 months. Any major adverse cardiac event (MACE) as defined by death, myocardial infarction, and target lesion revascularization (TLR) occurred in 30% of …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
